Lung Cancer Therapeutics Market Report by Therapy, Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer ), Distribution Channel, and Region 2024-2032

The global lung cancer therapeutics market size reached US$ 30,188.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 70,084.5 Million by 2032, exhibiting a growth rate (CAGR) of 9.52% during 2024-2032. The market is experiencing steady growth driven by the rapid increase in the incidence of lung cancer, which is aggravated by smoking and environmental pollution around the world, the further development of individualized treatment, including based on the gene profile, and the continuous advancement of technology for diagnosing the disease, to ensure early detection of the pathology.

Lung Cancer Therapeutics Market Analysis:

Major Market Drivers: The massive prevalence and mortality associated with lung cancer worldwide is creating a high lung cancer therapeutics market demand.

Key Market Trends: The market will develop in the direction of personalized medicine as an increasing number of therapies addressing particular genetic mutations in tumor cells are created. Additionally, the incorporation of AI and machine learning in the diagnostic processes enhancing the chances and precision of accessing such treatments is acting as one of the major lung cancer therapeutics market trends.

Geographical Trends: The market analysis states that North America leads the market regarding lung cancer therapeutics due to the robust healthcare structures, health expenditures, and early use of advanced oncology treatments. Asia Pacific region, including China and India, is driving the market based on rapidly growing healthcare awareness and improved healthcare delivery systems.

Competitive Landscape: According to the lung cancer therapeutics market overview, the market is highly competitive based on the existence of well-established pharmaceutical giants and new emerging biofirms. Additionally, major companies are innovating and expanding their product lines through research and development and partnerships.

Challenges and Opportunities: The high cost of new cancer medicines emerges as the main challenge to the lung cancer therapeutics revelations to the low- and middle-income economies, creating accessibility gaps. However, such challenges amplify as lung cancer therapeutics market recent opportunities for developing cost-effective generics and biosimilars.

Lung Cancer Therapeutics Market Trends:

Rising incidence of lung cancer worldwide

Another factor contributing to the lung cancer therapeutics market growth is the increasing incidence of lung cancer. The American Cancer Society made an estimation of lung cancer in the US by 2024. The number of new cancer occurrences should approximately equal 234,580 individuals, including 116,310 males and 118,270 females. The number of deaths will equal 125,070 deaths, which involves 65,790 male deaths and 59,280 female deaths. This can be supported by the exponentially growing global population and the prevalence of harmful factors causing lung cancer such as smoking, air and environmental pollution, and harmful workplace events. Thus, this is also influencing the lung cancer therapeutics market statistics. Due to the constantly increasing incidence of lung cancer, more active measures are needed. Accordingly, the development and improvement of methods, including drugs, for lung cancer treatment are constantly developing. Increased supply creates more reason for pharmaceutical companies to conduct tests and develop new ones and expand their assortment. Accordingly, demand for more effective drugs is growing. Thus, lung cancer therapeutics is the fastest-growing.

Innovations in personalized medicine

The lung cancer therapeutics market growth is increasing significantly with the development of personalized medicine, which treats each patient based on genetic features. In recent years, the drug industry has developed and produced drugs that precisely attack such mutations. These have proven to be more effective than chemotherapy, causing fewer side effects. The lung cancer therapeutics market forecast suggests that personalized medicine will become the basis of therapy for this oncology; this means an increase in the efficiency of therapy since the prescription will be more accurate. Furthermore, the growing emphasis on precision medicine is fueled by technological progress in diagnostics and an increased understanding of genetic factors influencing lung cancer progression. Consequently, the pharmaceutical industry's investment in personalized solutions continues to expand, aligning drug development with specific patient needs and substantially driving the lung cancer therapeutics market forward.

Continuous advancements in diagnostics and treatment

Technological innovations drive the market, particularly in diagnostics and treatment delivery. In addition, improved imaging and AI-assisted diagnostic tools allow lung cancer detection early and more accurately. Along with this, this notion is a game-changer for treatment efficacy and patient recovery. Apart from this, the lung cancer therapeutics market recent developments include the introduction of new and developing minimally invasive surgery techniques, enhanced radiation treatment approaches, and advanced drug-delivery systems, including nanoparticle-based chemo preparations. In addition, the accuracy and effectiveness of advanced technology cannot imagine a comfortable treatment and recoverable patient view. Furthermore, the combination of all these technologies is creating a positive market outlook.

Lung Cancer Therapeutics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on therapy, cancer type, and distribution channel.

Breakup by Therapy:

Targeted Therapy

Bevacizumab

Dabrafenib/Trametinib

Erlotinib Hydrochloride

Osimertinib

Others

Immunotherapy

Durvalumab

Nivolumab

Atezolizumab

Pembrolizumab

Radiation Therapy

External Beam

Internal Beam

Systemic

Chemotherapy

Targeted therapy accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the therapy. This includes targeted therapy (bevacizumab, dabrafenib/trametinib, erlotinib hydrochloride, Osimertinib and others); immunotherapy (durvalumab, nivolumab, atezolizumab and pembrolizumab); radiation therapy (external beam, internal beam and systemic); and chemotherapy. According to the report, targeted therapy represented the largest segment.

The therapy segment is the largest as it is more efficient and has fewer side effects compared to traditional chemotherapy. It includes drugs or other materials that can accurately recognize and kill cancer cells. This treatment is probably directed at the molecular and genetic features that differentiate cancer cells from others. In addition, the current level of understanding of genetic aspects of lung cancer allows the identification of many specific molecular targets and, correspondingly, agents that can prevent the activation of these targets. According to the lung cancer therapeutics market forecast, the development of molecular biology and genetics will consistently increase the number of targets and agents that could be used to combat the described disease. Hence, it is reasonable to suppose that the targeted therapy segment will continue developing due to the appearance of new potential targets and agents.

Breakup by Cancer Type:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Non-Small Cell Lung Cancer (NSCLC) holds the largest share of the industry

A detailed breakup and analysis of the market based on the cancer type have also been provided in the report. This includes non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). According to the report, non-small cell lung cancer (NSCLC) accounted for the largest lung cancer therapeutics market share.

The non-small cell lung cancer segment holds the largest share in the market due to its high prevalence. Individually, the subtypes share pathological variations, but they progress more slowly than small-cell lung cancer. As such, the high global prevalence of NSCLC creates a sizable lung cancer therapeutics market demand for the different subtypes, thereby incentivizing pharmaceutical companies and researchers to focus on developing therapies and immunotherapies that can treat the subtype gene and molecular distinctions effectively. In addition, the changing molecular pathogenesis capacity for NSCLC also ensures that the development of precision medicine causes NSCLC to have a correlation with the market.

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Other

Hospital pharmacies represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, online pharmacies, and others. According to the report, hospital pharmacies represented the largest segment.

Hospital pharmacies are the largest channel of distribution in the lung cancer therapeutics segment due to the complicated and advanced nature of the therapies for the disease. Doctors require a controlled environment to administer treatments, including chemotherapy solutions, which need to be carefully regulated to avoid side effects. According to the lung cancer therapeutics market analysis, most lung cancer therapies are for inpatients given the need for complex therapies such as chemotherapy, targeted therapy, and immunotherapies According to the lung cancer therapeutics market analysis, most lung cancer therapies are for inpatients given the need for complex therapies such as chemotherapy, targeted therapy, and immunotherapies. Additionally, hospital pharmacies are critical in facilitating integrated lung cancer care as the patient can access all the required treatments immediately and from the same hospital that can coordinate oncology, surgery, and radiology departments. Apart from this, the centralization of centrality ensures the patient undergoes therapy with minimal delays which improves the effectiveness of the therapeutics. Furthermore, the demand for infrastructure and personnel expertise is increasing the lung cancer therapeutics market revenue.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest lung cancer therapeutics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for lung cancer therapeutics.

North America has the largest regional lung cancer therapeutics market share due to high disease prevalence, advanced healthcare infrastructure, and one of the highest healthcare spender factors. Along with this, high government contribution and private sector support in the US and Eurozone countries, spent on research and development, also play a key role in the growth of the North American market. Furthermore, the accelerating investments to develop technologies and initiatives to diagnose and treat lung cancer are influencing lung cancer therapeutics market revenue positively. As the lung cancer therapeutics market growth trend shows, in the past decade, various targeted therapies and immunotherapies have been developed and used in the treatment of lung cancer. Furthermore, the regulatory environment across the region also has a friendly policy of fast-track cancer drugs. Moreover, the high levels of patient awareness across the region, and insurance coverage ensures North America continues to dictate the global market.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the lung cancer therapeutics industry include:

AbbVie Inc.

Amgen Inc.

AstraZeneca Plc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Company

Daiichi Sankyo Company Limited

Eli Lilly and Company

GSK PLC

Merck & Co. Inc.

Novartis AG

Pfizer Inc.

Roche Holding AG

Takeda Pharmaceutical Company Limited

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The major lung cancer therapeutics market companies swiftly develop their product portfolios. As R&D remains critically important in their aim to expand, these companies, Roche, Pfizer, AstraZeneca, and other influential giants, are recognized as the most innovative pharmaceutical firms globally. In particular, they are developing targeted therapy and immunotherapy, which showed encouraging outcomes in addressing numerous lung cancer subtypes. Therefore, this is acting as one of the major market trends. In addition, the companies invest in advanced clinical trials to develop new indication opportunities, significantly expanding the imaginable market for their products. Furthermore, the M&A activity is also very high in the industry where several companies attempt to purchase all competitors and utilize all the latest technology available on the market. Thus, the need to stay competitive in the market for therapeutic results and improved patient outcomes.

Lung Cancer Therapeutics Market News:

March 26, 2024: AbbVie Inc. entered into a definitive agreement to acquire clinical-stage biopharmaceutical company Landos Biopharma for $212.5 million. The optimal acquisition strengthens AbbVie's pipeline in its target therapeutic area of inflammatory and autoimmune diseases.

March 19, 2024: AstraZeneca Plc acquired oncology biotech Fusion Pharmaceuticals for $2.4bn, acquiring expertise in a developing field of a less toxic and more targeted form of radiotherapy to catch up with the Swiss Novartis.

Key Questions Answered in This Report:

• How has the global lung cancer therapeutics market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global lung cancer therapeutics market?
• What is the impact of each driver, restraint, and opportunity on the global lung cancer therapeutics market?
• What are the key regional markets?
• Which countries represent the most attractive lung cancer therapeutics market?
• What is the breakup of the market based on the therapy?
• Which is the most attractive therapy in the lung cancer therapeutics market?
• What is the breakup of the market based on the cancer type?
• Which is the most attractive cancer type in the lung cancer therapeutics market?
• What is the breakup of the market based on the distribution channel?
• Which is the most attractive distribution channel in the lung cancer therapeutics market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global lung cancer therapeutics market?